Table 1

Summary of results in the individual randomised, double blind, placebo controlled trials.
Author	Number of patients	Quality score	Duration (months)	ITT or PP	Symptom score	Max urinary flow rate (mL/s)	Prostate volume (cm3)

McConnell et al, 1998 PLESS	3040	4	48	PP	++	++	++
Marbergher et al, 1998 PROWESS	2902	5	24	PP	++	++	++
Byrnes et al, 1995	2417	3	12	ITT	+	No data
Tenover et al, 1997	2112	3	12	PP	++	No data
Andersen et al, 1995	707	3	24	PP	++	++	++
Lepor et al, 1996 VA cooperative study.	615	4	12	PP	-	-	++
Nickel et al, 1996 PROSPECT	613	5	24	ITT	++	++	++
Gormley et al, 1992 North American study	598	3	12	ITT	++	++	++
Finasteride study group, 1993 International study	501	3	12	PP	++	+	++
Beisland et al, 1992	182	3	6	ITT	+	+	++
Abrams et al, 1999	121	3	12	PP	-	+	++
Kirby et al, 1992	50	4	3	PP	++	++	-
Yu et al, 1995	50	3	6	PP	+	+	+
Marks et al, 1997	41	4	6	PP	-	-	++
Tammela & Kontturi, 1993	36	3	6	ITT	No data	-	++

Studies with finasteride plus additional interventions
Lukkarinen et al, 1999	61	3	24	PP	-	-	++
Isotalo et al, 2001	55	4	18	ITT	-	+	++

+ p < 0.05 ++ p < 0.01 – No significant difference between finasteride and placebo ITT Intention to treat analysis – all randomised patients PP Per protocol analysis – may have included men who discontinued treatment
Edwards and Moore BMC Urology 2002 2:14 doi:10.1186/1471-2490-2-14